Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaxis Ltd ( (AU:SNT) ) has shared an update.
Syntara Limited reported a significant improvement in its financial performance for the year ended June 30, 2025, with revenues increasing by 19.2% to $7.63 million. The company’s loss after tax decreased by 47.7% to $7.919 million, reflecting a positive trend in financial health, although no dividends were declared for the period.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 7,328,631
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$42.32M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.